A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC 698037) in Combination With Cisplatin (NSC 119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix.

Trial Profile

A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC 698037) in Combination With Cisplatin (NSC 119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2015

At a glance

  • Drugs Pemetrexed (Primary) ; Cisplatin
  • Indications Cervical cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Nov 2014 Status changed from recruiting to discontinued, according to M.D. Anderson Cancer Center record.
    • 09 Jun 2010 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
    • 28 Aug 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top